Get to know our team of experts
igniting change in GI therapies
Gary S. Jacob, Ph.D.
Chairman of the Board and CEO
Gary Jacob, Ph.D., has served as our President, Chief Executive Officer and a Director since July 2008. He is a co-inventor of Synergy’s uroguanylin-based GI platform technology for functional GI disorders and inflammatory bowel disease. He has over 25 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines, including research and development, operations and business development. Dr. Jacob currently serves as a director of Trovagene, Inc., a public diagnostics company and Chairman of the Board of ContraVir Pharmaceuticals, Inc. since May 2013. He served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. He also served as Chief Scientific Officer of Synergy from 1999 to 2003. Prior to his involvement with Callisto and Synergy, Dr. Jacob was at Monsanto/G.D. Searle, where he served as Director of Glycobiology and Monsanto Science Fellow, specializing in the field of Glycobiology and drug discovery. From 1986 to 1990, he managed the G.D. Searle Glycobiology Group located at Oxford University, England.
Dr. Jacob earned a B.S. in Chemistry from the University of Missouri, and holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison.
Kunwar Shailubhai, Ph.D.
Executive Vice President and Chief Scientific Officer
Kunwar Shailubhai, Ph.D., M.B.A. has served as our Chief Scientific Officer since July 2008. He is a co-inventor of Synergy’s uroguanylin-based GI platform technology for functional GI disorders and inflammatory bowel disease. From 2003 until July 2008, Dr. Shailubhai served as Senior Vice President, Drug Discovery, of Synergy Pharmaceuticals Inc. From 2001 to 2003, he held the position of Vice President, Drug Discovery at Synergy Pharmaceuticals, Inc. where he was responsible for the preclinical development of Synergy's two lead product candidates, plecanatide and dolcanatide, which are both analogs of uroguanylin. Between 1993 and 2000, he was with Monsanto Company, serving as Group Leader of the cancer chemoprevention group. He previously served as a Senior Staff Fellow at the National Institutes of Health, and as an Assistant Professor at the University of Maryland.
Dr. Shailubhai received his Ph.D. in microbiology from the University of Baroda, India, and his MBA from the University of Missouri, St. Louis.
Patrick H. Griffin, M.D., FACP
Executive Vice President and Chief Medical Officer
Patrick Griffin, M.D., is a board-certified physician in both internal medicine and gastroenterology, and is a Fellow of the American College of Physicians. He received his medical degree from Columbia University, completing a residency in internal medicine at Presbyterian Hospital in New York, and a fellowship in gastroenterology at Brigham and Women's Hospital in Boston. Following his residency and fellowship, Dr. Griffin joined the medical faculty of Columbia College of Physicians and Surgeons, where he held a number of academic, clinical research, teaching and management positions, as well as a solo private practice in New York. He subsequently moved to the biopharmaceutical industry, where he held positions of increasing responsibility, first at Forest Laboratories, and subsequently at Sanofi-Aventis, culminating with his appointment as Associate Vice-President, Clinical Development.
Troy Hamilton, Pharm.D.
Executive Vice President and Chief Commercial Officer
Troy Hamilton, Pharm.D., has served as our Executive Vice President, Chief Commercial Officer since February 2016 and as our Senior Vice President, Chief Commercial Officer from July 2015 to February 2016. Troy has over 20 years of experience in the pharmaceutical industry, with an emphasis on general management, P&L responsibility, commercialization, partnerships, acquisitions, and global product launches in the gastroenterology and primary care markets. Prior to joining Synergy, Troy held multiple commercial leadership roles over a nine year period at Shire Pharmaceuticals. Most recently, he was Vice President, Product Strategy and Commercial Lead for Shire's Gastrointestinal (GI) Business Unit. Prior to this, he served as Vice President of GI International Marketing as part of a two year assignment based in Belgium, and as General Manager for the Inflammatory Bowel Disease franchise globally. Troy joined Shire in 2006 as the Head of US Marketing, leading the successful launch of Lialda® and continued commercialization of Pentasa®. Previously, he spent 10 years at Johnson & Johnson's Janssen Pharmaceuticals and McNeil Specialty Products in a number of in-house and field-based leadership roles within GI/primary care brand management, strategic planning, new product development, and medical services. Troy holds a BS in Pharmacy and PharmD from the University of the Sciences in Philadelphia and an MBA from St. Joseph's University.
Executive Vice President and Chief Strategy Officer
Mr. Garcia, M.B.A, has over 22 years of experience in various commercial, new product planning and business development roles. Prior to joining Synergy in March 2014, he served as Vice President of Global Business Development at Aptalis Pharma, a privately held specialty company focused on the gastrointestinal and cystic fibrosis markets which was acquired by Forest Labs in early 2014. From 2006 to 2010, he served as Vice President of US Commercial Operations and New Product Development at Aspreva Pharmaceuticals, which was acquired by Zurich-based Vifor Pharmaceuticals. Earlier in his career, he served in various U.S. and international leadership roles of increasing responsibility in companies like Eli Lilly & Co and Pfizer.
Mr. Garcia received a Bachelor's Degree in Business Administration from Concordia University in Montreal, Quebec, and an M.B.A. from the Ivey Business School at Western University in London, Ontario.
Gary G. Gemignani
Executive Vice President and Chief Financial Officer
Mr. Gemignani’s career in healthcare spans over three decades, including senior management positions at several pharmaceutical and biopharmaceutical companies. Most recently, he served as Chief Executive Officer and Chief Financial Officer of Biodel, Inc., (now Albireo), overseeing business and strategic planning, operations, and financing activities of the Company. During his tenure, Mr. Gemignani successfully led the reverse merger with Albireo and managed several corporate restructurings to strengthen Albireo’s overall financial position. Prior to this role, Mr. Gemignani served in senior and executive financial and operational roles with multiple public and private companies including Coronado Biosciences, Inc., Gentium S.p.A., Novartis Pharmaceutical Corp. and Wyeth. Mr. Gemignani began his career with Arthur Andersen and Company and holds a Bachelor’s of Science from St. Peter’s College.
Bernard Denoyer has served as our Senior Vice President, Finance and Secretary since July 2008. Mr. Denoyer has also served as the Senior Financial Officer and Secretary of Callisto Pharmaceuticals, Inc. (NASDAQ:CLSP) from January 2004 until January 2013, when Callisto merged with Synergy, and Chief Financial Officer and Secretary of ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) from May 2013 until March 2014, when ContraVir was spun off to Synergy shareholders. From 2001 through 2003, Mr. Denoyer was an independent consultant providing interim CFO services to emerging technology companies, including Callisto. From 1994 through 2000, Mr. Denoyer served as Chief Financial Officer and Senior Vice President at META Group, Inc., where he was instrumental in their 1995 IPO. From 1990 to 1993 he served as Vice President Finance of Environetics, Inc., a pharmaceutical water diagnostic business.
Mr. Denoyer received a B.A. in Economics from Fairfield University, earned his M.B.A. in Finance from the Columbia Business School and his CPA while at Ernst & Young.